Add to ORKGA phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cance
SIGLEAvailable from British Library Document Supply Centre-DSC:3578.772(85) / BLDSC - British Librar...
Several schedules of 5-fluorouracil (FU) and irinotecan (IRI) have been shown to improve overall sur...
The aim of this prospective study was to assess the efficacy, clinical benefit and safety of CPT-11 ...
Purpose: This multicenter phase II study was designed to assess the efficacy of the alternating sche...
Background: Irinotecan is a topoisomerase I inhibitor that prolongs survival as second- line therapy...
A biweekly regimen of irinotecan 200 mg/m2 on day 1 and levo-leucovorin (LV) 250 mg/m2 plus 5-fluoro...
Irinotecan is active against colorectal cancer in patients whose disease is refractory to fluorourac...
A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fl...
Introduction This multicenter phase II study determined the efficacy and safety of new daily oral S-...
Background: Irinotecan, in combination with 5-fluorouracil (5-FU) and a high dose of leucovorin (LV...
BACKGROUND: Simvastatin has demonstrated anti-tumor activity in preclinical studies via tumor cell s...
The recent incorporation of irinotecan (CPT-11) for the management of advanced colorectal cancer has...
This phase III study compared the safety and efficacy of the following three different irinotecan-co...
The efficacy of combination therapy with irinotecan and capecitabine has been demonstrated for the f...
BACKGROUND: A biweekly regimen of irinotecan 200 mg/m2 on day 1 and levo-leucovorin (LV) 250 mg/m2 ...
SIGLEAvailable from British Library Document Supply Centre-DSC:3578.772(85) / BLDSC - British Librar...
Several schedules of 5-fluorouracil (FU) and irinotecan (IRI) have been shown to improve overall sur...
The aim of this prospective study was to assess the efficacy, clinical benefit and safety of CPT-11 ...
Purpose: This multicenter phase II study was designed to assess the efficacy of the alternating sche...
Background: Irinotecan is a topoisomerase I inhibitor that prolongs survival as second- line therapy...
A biweekly regimen of irinotecan 200 mg/m2 on day 1 and levo-leucovorin (LV) 250 mg/m2 plus 5-fluoro...
Irinotecan is active against colorectal cancer in patients whose disease is refractory to fluorourac...
A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fl...
Introduction This multicenter phase II study determined the efficacy and safety of new daily oral S-...
Background: Irinotecan, in combination with 5-fluorouracil (5-FU) and a high dose of leucovorin (LV...
BACKGROUND: Simvastatin has demonstrated anti-tumor activity in preclinical studies via tumor cell s...
The recent incorporation of irinotecan (CPT-11) for the management of advanced colorectal cancer has...
This phase III study compared the safety and efficacy of the following three different irinotecan-co...
The efficacy of combination therapy with irinotecan and capecitabine has been demonstrated for the f...
BACKGROUND: A biweekly regimen of irinotecan 200 mg/m2 on day 1 and levo-leucovorin (LV) 250 mg/m2 ...
SIGLEAvailable from British Library Document Supply Centre-DSC:3578.772(85) / BLDSC - British Librar...
Several schedules of 5-fluorouracil (FU) and irinotecan (IRI) have been shown to improve overall sur...
The aim of this prospective study was to assess the efficacy, clinical benefit and safety of CPT-11 ...